All

The Sanctuary Group raises €5 million to roll out its sports studios across France
12 January 2026

The Sanctuary Group raises €5 million to roll out its sports studios across France

Specializing in fitness studios, French startup The Sanctuary Group has announced that it has raised €4.7 million in funding. This will enable it to accelerate the rollout of...

Read more
SkillCorner Secures $60M Growth Investment to Accelerate Global Sports Data Innovation
17 December 2025

SkillCorner Secures $60M Growth Investment to Accelerate Global Sports Data Innovation

SkillCorner is pleased to announce a $60 million growth investment from Silversmith Capital Partners, marking an important step forward in our mission to deliver world-leading...

Read more
Wealthpilot merges with Finaplus
10 December 2025

Wealthpilot merges with Finaplus

The Munich-based Software-as-a-Service (SaaS) platform Wealthpilot has now joined the Finaplus Group. This strengthens Finaplus' platform offering in the Wealth-as-a-Service...

Read more
Merchants entrust SumUp’s Business Account with over €1 Billion in Deposits
10 December 2025

Merchants entrust SumUp’s Business Account with over €1 Billion in Deposits

Global financial technology company SumUp today announced its merchant business account ecosystem has achieved two major milestones: surpassing €1 billion in customer...

Read more
Vertero Establishes Scientific Advisory Board to Advance Innovation in Neurodegenerative Diseases
10 December 2025

Vertero Establishes Scientific Advisory Board to Advance Innovation in Neurodegenerative Diseases

Vertero Therapeutics, a clinical-stage biotechnology company breaking barriers in neurodegenerative disease treatment, today announced the appointment of five globally...

Read more
MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival
8 December 2025

MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Read more
First patient dosed in Citryll’s phase IIA Hidradenitis Suppurativa Trial
8 December 2025

First patient dosed in Citryll’s phase IIA Hidradenitis Suppurativa Trial

Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Extracellular Traps (ETs), today announces the...

Read more
Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial
2 December 2025

Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial

Enterome, a clinical-stage company pioneering OncoMimics™ peptides, a new class of off-the-shelf, multi-targeted in vivo immune therapies that induce a fast and potent...

Read more
MaaT Pharma announces the successful completion of its Global Offering of €9.1 million
14 November 2025

MaaT Pharma announces the successful completion of its Global Offering of €9.1 million

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Read more
Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $ 401M)
30 October 2025

Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $ 401M)

• New investors Fidelity Management & Research Company, Janus Henderson Investors and Blackstone Multi-Asset Investing join Series C syndicate led by Venrock Healthcare...

Read the press release